The T2Candida® Panel is the first and only direct-from-blood fungal pathogen detection assay, providing same-day results directly from a whole blood specimen for the most clinically relevant fungi.
T2Candida’s greatest clinical utility is for patients in any of these conditions1:
- Admitted to the ICU
- Have febrile neutropenia
- Have septic shock
- Have an LVAD and evidence of active infection
- In ICU at high risk for candidemia
Reduction in mortality rates: Candida infections have an overall mortality rate of 40%, but if patients receive targeted treatment within 12 hours, the mortality rate can be reduced to 11%.2,3 T2Candida provides a clear and compelling solution, with results in just hours without waiting for slow-growing fungal infections, which are often mistaken as bacterial infections, to reach positivity.
Unprecedented speed and accuracy: The T2Candida Panel pivotal clinical trial demonstrated results in 3 to 5 hours.4 All other FDA-cleared Candida diagnostic methods require a positive blood culture. Blood culture misses up to half of infections and often will take 2 to 8 days to become positive.5 Only then can identification be performed. In most cases, a negative result is not confirmed for 5 days after collection and processing of the blood culture.
Faster targeted therapy: Faster time to appropriate therapy has been consistently demonstrated to reduce overall length of stay in the hospital and ICU and results in a savings of $30,000 per patient.6 See how Henry Ford in Michigan and Lee Health in Florida have demonstrated faster targeted therapy for patients in clinical care for more than 24 hours.7,8
Improved stewardship and pharmacy savings: Hospitals – including Lee Health,8 Huntsville Hospital,9 and University of Pittsburgh Medical Center10 – have reported antifungal savings from negative test results, which can more than offset the full cost of the test.
Watch T2Candida at work.
Contact us to request a demo of the T2Candida Panel!